- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports First Quarter 2024 Results
- Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
- Royalty Pharma Declares Second Quarter 2024 Dividend
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.11 |
---|---|
High | 26.23 |
Low | 25.83 |
Bid | 25.79 |
Offer | 26.06 |
Previous close | 26.19 |
Average volume | 2.78m |
---|---|
Shares outstanding | 597.44m |
Free float | 385.55m |
P/E (TTM) | 14.69 |
Market cap | 15.65bn USD |
EPS (TTM) | 1.78 USD |
Annual div (ADY) | 0.84 USD |
---|---|
Annual div yield (ADY) | 3.21% |
Div ex-date | May 16 2024 |
Div pay-date | Jun 14 2024 |
Data delayed at least 15 minutes, as of Jul 02 2024 21:00 BST.
More ▼